当施設における stage IV 悪性黒色腫の予後と治療の現状 Prognostic factors in stage IV malignant melanoma

この論文にアクセスする

この論文をさがす

著者

抄録

To identify factors that are prognostic for survival in patients with stage IV malignant melanoma, a retrospective analysis was performed at the authors' institutions between 1976 and 1999. The median survival time of 53 stage IV patients was 7.1 months. Univariate analysis showed that initial site of metastasis (p=0.05) was significant prognostic factor. Conversely, the stage of disease preceding distant metastasis (p=0.59), disease free interval before distant metastasis (p=0.66), times at distant metastasis (p=0.92), and treatment modalities (p=0.17) were not significantly prognostic for survival. The response rates to DAV (dacarbazine, nimustine, vincristine), CDV (cisplatin, dacarbazine, vindesine), and DACTam (dacarbazine, nimustine, cisplatin, tarnoxifen) regimens were 22.2%, 9.1%, 0%, respectively. There was no statistically significant difference in response rates among the treatment arms (p=0.23). Although a variety of chemotherapeutic drug combinations have been explored over the years, they have not proven to be superior to dacarbazine alone. We need to develop new strategies for the treatment of stage IV melanoma. [<i>Skin Cancer (Japan)</i> 2001; 16: 222-227]

収録刊行物

  • Skin cancer : official organ of the Japanese Society for Skin Cancer = 皮膚悪性腫瘍研究会機関誌

    Skin cancer : official organ of the Japanese Society for Skin Cancer = 皮膚悪性腫瘍研究会機関誌 16(2), 222-227, 2001-10-31

    日本皮膚悪性腫瘍学会

参考文献:  24件中 1-24件 を表示

被引用文献:  4件中 1-4件 を表示

各種コード

  • NII論文ID(NAID)
    10013030609
  • NII書誌ID(NCID)
    AN10087647
  • 本文言語コード
    JPN
  • 資料種別
    REV
  • ISSN
    09153535
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ